These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 15384026

  • 1. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
    Phakdeekitcharoen B, Leelasa-nguan P.
    Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
    [Abstract] [Full Text] [Related]

  • 2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 3. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V, Eiam-Ong S, Kanjanabuch T, Wathanavaha A, Pansin P.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [Abstract] [Full Text] [Related]

  • 4. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 6. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M, Høj Nielsen A, Strandgaard S, Kamper AL.
    Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
    [Abstract] [Full Text] [Related]

  • 7. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 8. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A, Tamura K, Dejima T, Ozawa M, Wakui H, Masuda S, Azuma K, Tsurumi-Ikeya Y, Mitsuhashi H, Okano Y, Kokuho T, Sugano T, Ishigami T, Toya Y, Uchino K, Tokita Y, Umemura S.
    Nephron Clin Pract; 2009 Jul; 112(1):c31-40. PubMed ID: 19342867
    [Abstract] [Full Text] [Related]

  • 9. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
    Saito M, Nakayama D, Takada M, Hirooka K, Yasumura Y.
    J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
    [Abstract] [Full Text] [Related]

  • 10. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 11. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC, Figueiredo AE, Barretti P, Pecoits-Filho R, de Moraes TP, BRAZPD Investigators.
    Am J Nephrol; 2017 Jan; 46(2):150-155. PubMed ID: 28738355
    [Abstract] [Full Text] [Related]

  • 12. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
    Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA, CHARM Program Investigators.
    J Am Coll Cardiol; 2007 Nov 13; 50(20):1959-66. PubMed ID: 17996561
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB.
    J Hypertens Suppl; 2006 Mar 13; 24(1):S3-7. PubMed ID: 16601570
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 13; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 20. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG, Serbul VM, Ageev FT.
    Ter Arkh; 2009 Jan 13; 81(5):64-71. PubMed ID: 19537590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.